Clinical Trials Sponsored by Bayer S.p.A

Total 3169 results

Fidia Farmaceutici s.p.a.

Recruiting

An Open Label, Randomized-controlled Trial to Assess Efficacy Safety of HYALODISC With Physical Exercise Program

Degenerative Disc Disease(DDD)

Italy, Switzerland
Limacorporate S.p.a
NAMSA

Recruiting

SMR Stemless Reverse vs SMR Reverse Shoulder System

Arthroplasty, Replacement

United States
Fidia Farmaceutici s.p.a.

Recruiting

Effectiveness of Tricortin 1000 in Patients Affected by Chronic Low Back Pain

Low Back Pain, Mechanical

Italy
GreenBone Ortho S.p.A.

Completed

Pre-market Study to Evaluate Safety and Performance of GreenBone Implant (GreenBric)

Bone Substitutes

United Kingdom
Dompé Farmaceutici S.p.A

Completed

Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study) (NGF0121)

Dry Eye

United States, Italy
GreenBone Ortho S.p.A.

Terminated

Pre-market Study to Evaluate Safety and Performance of GreenBone Implant (Long Bone Study)

Bone Substitutes | Bone Defect

Bosnia and Herzegovina, Israel, Italy, Serbia, Slovenia, United Kingdom
Chiesi Farmaceutici S.p.A.

Terminated

Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER) (PIONEER)

Pediatric Perioperative Blood Pressure Management

United States
Dompé Farmaceutici S.p.A

Terminated

Ascending Dose Tolerability Trial and PK Assessment in Healthy Volunteers After Single & Multiple Oral Intake of DF2755A

no Condition

France
Dompé Farmaceutici S.p.A

Completed

A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye

Dry Eye Syndrome

United States
Dompé Farmaceutici S.p.A

Completed

A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes

Diabetes Mellitus, Insulin-Dependent

Germany, Belgium, Italy
Dompé Farmaceutici S.p.A

Completed

Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis. (REPARO)

Keratitis | Neurotrophic Keratitis | Corneal Ulcer

Germany, Italy, France, Poland, Spain, United Kingdom
Dompé Farmaceutici S.p.A

Completed

A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP) (Lumos)

Retinitis Pigmentosa

Italy
Chiesi Farmaceutici S.p.A.

Completed

Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects

Chronic Obstructive Pulmonary Disease

Bulgaria
Chiesi Farmaceutici S.p.A.

Completed

Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects

Chronic Obstructive Pulmonary Disease (COPD) | COPD

United Kingdom
Dompé Farmaceutici S.p.A

Completed

A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers

no Condition

Switzerland
Janssen-Cilag S.p.A.

Completed

A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis (GULLIVER)

Psoriasis

Italy
Dompé Farmaceutici S.p.A

Completed

Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.

SARS CoV 2 Infection

France, Spain, Italy
Chiesi Farmaceutici S.p.A.

Terminated

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration (LISPAP)

Respiratory Distress Syndrome (RDS)

United States
Fidia Farmaceutici s.p.a.

Completed

Efficacy and Safety of the Use of Ophthalmic Viscosurgical Devices (OVD) FIDIAL PLUS vs IAL®-F During Cataract Surgery

Cataract

Italy
Chiesi Farmaceutici S.p.A.

Available

Expanded Access to Velmanase Alfa

Alpha-Mannosidosis
Chiesi Farmaceutici S.p.A.

Completed

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD (TRIFORCE)

Chronic Obstructive Pulmonary Disease

Germany
Dompé Farmaceutici S.p.A

Completed

Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK

Neurotrophic Keratitis

United States
Chiesi Farmaceutici S.p.A.

Completed

A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma

Asthma

United Kingdom
Dompé Farmaceutici S.p.A

Completed

A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males

No Condition

United Kingdom
SOFAR S.p.A.
1Med

Completed

L. Casei DG® in Patients With Irritable Bowel Syndrome. (PROBE2)

IBS - Irritable Bowel Syndrome

Italy
Chiesi Farmaceutici S.p.A.

Terminated

Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma (PERSEA)

Asthma; Eosinophilic

Bulgaria
Chiesi Farmaceutici S.p.A.

Terminated

A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)

Neonatal Respiratory Distress Syndrome

Italy
Janssen-Cilag S.p.A.

Completed

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting (EVIdeNCE)

Leukemia, Lymphocytic, Chronic, B-Cell

Italy
Chiesi Farmaceutici S.p.A.

Completed

Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients

Pulmonary Disease, Chronic Obstructive | Asthma

Germany
Chiesi Farmaceutici S.p.A.

Completed

2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients (TRIBUTE)

Chronic Obstructive Pulmonary Disease (COPD)

Italy
Chiesi Farmaceutici S.p.A.

Completed

Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration (GLY2)

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF)

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment. (TRIPLE10)

Chronic Obstructive Pulmonary Disease (COPD)

Poland
Chiesi Farmaceutici S.p.A.

Completed

Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate

Pulmonary Disease, Chronic Obstructive

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients (TRIPLE 4)

COPD

Poland
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients (Trigon)

Chronic Obstructive Pulmonary Disease

Bulgaria, Germany, Poland, United Kingdom
Alfasigma S.p.A.
Cromsource

Terminated

A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention (STOP-PER)

Crohn Disease

Italy
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers

Asthma

Belgium
Chiesi Farmaceutici S.p.A.

Completed

Effect of the Use of an add-on Device Connected to a Smartphone App on Difficult-to-treat Asthmatic Patient's Adherence (ADVICE)

Asthma

United Kingdom
AGC Biologics S.p.A.

Terminated

Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia (TK008)

Acute Leukemia (Category)

Israel, United States, Germany, France, Spain, Belgium, Italy, Greece, Lithuania, Portugal
Chiesi Farmaceutici S.p.A.

Completed

Triple in Asthma Dose Finding (Triskel)

Asthma

Bulgaria, Germany, Hungary, Italy, Poland, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA (TRIMARAN)

Asthma

Germany
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)

Asthma

Bulgaria, Germany, Italy, Netherlands, Poland
Chiesi Farmaceutici S.p.A.

Completed

Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)

COPD (Chronic Obstructive Pulmonary Disease)

China, Korea, Republic of, Taiwan
Chiesi Farmaceutici S.p.A.

Completed

A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis

Cystic Fibrosis | Non-Cystic Fibrosis Bronchiectasis

Germany
Chiesi Farmaceutici S.p.A.

Withdrawn

Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis (SHAMAN)

Alpha-Mannosidosis
Janssen-Cilag S.p.A.

Completed

An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate (DIAMANTE)

Human Immunodeficiency Virus (HIV)

Italy
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study (Curpap)

Respiratory Distress Syndrome, Newborn

Italy, Spain, Czechia, France, Portugal
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

Asthma
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old (PAED4)

Asthma in Children

Denmark

3

Subscribe